<DOC>
	<DOC>NCT01103089</DOC>
	<brief_summary>The purpose of the study is to determine patient characteristics from patients that have used Iressa for a period of minimal 3 years.</brief_summary>
	<brief_title>Observations From Long Term Responders in the Gefitinib (Iressa) Expanded Access Program (EAP)</brief_title>
	<detailed_description />
	<mesh_term>Carcinoma, Non-Small-Cell Lung</mesh_term>
	<mesh_term>Gefitinib</mesh_term>
	<criteria>Participation in the gefitinib Expanded Access Program Patient still uses gefitinib in September 2009</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2011</verification_date>
	<keyword>NSCLC</keyword>
	<keyword>EGFR</keyword>
	<keyword>gefitinib</keyword>
	<keyword>observational</keyword>
</DOC>